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Background: Insomnia is common in primary care, can persist after co-morbid conditions are treated, and may
require long-term medication treatment. A potential alternative to medications is cognitive behavioral therapy for
insomnia (CBT-I).
Methods: In accordance with PRISMA guidelines, we systematically reviewed MEDLINE, EMBASE, the Cochrane
Central Register, and PsycINFO for randomized controlled trials (RCTs) comparing CBT-I to any prescription or non-
prescription medication in patients with primary or comorbid insomnia. Trials had to report quantitative sleep
outcomes (e.g. sleep latency) in order to be included in the analysis. Extracted results included quantitative sleep
outcomes, as well as psychological outcomes and adverse effects when available. Evidence base quality was
assessed using GRADE.
Results: Five studies met criteria for analysis. Low to moderate grade evidence suggests CBT-I has superior
effectiveness to benzodiazepine and non-benzodiazepine drugs in the long term, while very low grade evidence
suggests benzodiazepines are more effective in the short term. Very low grade evidence supports use of CBT-I to
improve psychological outcomes.
Conclusions: CBT-I is effective for treating insomnia when compared with medications, and its effects may be more
durable than medications. Primary care providers should consider CBT-I as a first-line treatment option for insomnia.
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The prevalence of insomnia in primary care patients is
as high as 69% [1,2] compared to 33% in the general
population [3]. Insomnia can exist as a primary disorder
or co-morbid with other conditions including depression
[4] and chronic pain. In the past insomnia was consid-
ered to be a symptom of these conditions with the as-
sumption that treatment of these ‘primary’ conditions
would lead to the resolution of insomnia, eliminating the
need for targeted insomnia treatment. There is now evi-
dence to suggest that insomnia often persists following
resolution of these ‘primary’ conditions, and that it gen-
erally does not spontaneously resolve over time if left
untreated [5]. Insomnia is independently associated
with significant morbidity including fatigue, impaired* Correspondence: mdmitchell@uphs.upenn.edu
1Center for Evidence-based Practice, University of Pennsylvania Health
System, 3535 Market St. Mezzanine Suite 50, Philadelphia, PA 19104, USA
Full list of author information is available at the end of the article
© 2012 Mitchell et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orconcentration and memory, irritability, difficulty in
interpersonal relationships, decreased quality of life,
and increased risk of new-onset psychiatric illness [1,6-
9]. In addition, there is evidence that insomnia may
confer risk for medical illness including hypertension,
heart disease, and diabetes [10,11], and is associated
with increased overall health care costs [9].
The most common approach to the management of in-
somnia is medication treatment. Numerous trials have
documented moderate efficacy with benzodiazepine re-
ceptor agonists [12,13]. The advantages of medications
are that they are widely available and, when effective,
lead to clinical improvement rapidly. The disadvantages
are the potential for side-effects, dependence, and toler-
ance over time. Perhaps the most important disadvan-
tage is that medications are usually not curative, leading
to long-term treatment over many years despite a lack of
safety and efficacy data for their long-term use beyond
1–2 years.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ioral therapy for insomnia (CBT-I). CBT-I is a non-
pharmacological approach to treatment comprised of
several strategies. The goal of CBT-I is to target those
factors that may maintain insomnia over time, such as
dysregulation of sleep drive, sleep-related anxiety, and
sleep-interfering behaviors. This is accomplished by
establishing a learned association between the bed and
sleeping through stimulus control, restoring homeostatic
regulation of sleep through sleep restriction, and altering
anxious sleep-related thoughts through cognitive restruc-
turing. By changing sleep-related behaviors and thoughts,
CBT-I may target those factors that cause insomnia to
persist over time. CBT-I is delivered over the course of
4–8 sessions that occur weekly or every other week for
30–60 minutes each. There are two main disadvantages
to CBT-I. First, during the first few weeks of treatment
there is often an acute reduction in total sleep time that
can lead to the side effect of increased daytime sleepiness
which, for some, is enough to lead them to drop out of
treatment. Second, improvements from CBT-I are typic-
ally not seen until 3–4 weeks into treatment. While a
few research studies have examined the efficacy of nurse-
led CBT-I in primary care settings [14], in current clin-
ical practice it is usually necessary to refer out to indivi-
duals with specialized training in this treatment. It
should be noted that the core therapies for CBT-I sub-
stantially differ from other forms of CBT and it is for this
reason that the abbreviation CBT-I denotes this form of
CBT specifically for insomnia [15].
Treating insomnia with CBT-I, as opposed to medica-
tion, has a number of potential advantages, including
fewer known side effects, and an explicit focus on treat-
ing the factors that may be responsible for perpetuating
chronic insomnia in an effort to produce more durable
effects. Some patients also prefer non-medication treat-
ments [12,16,17]. Providers often have negative attitudes
towards hypnotics as well, and prefer to reduce their pre-
scriptions of such medications [18]. These advantages of
CBT-I suggest that it might be a viable option for the
treatment of insomnia [12,17].
Evidence suggests that CBT-I is effective when com-
pared with placebos [19,20]. A new systematic review
[21] meta-analyzes evidence from 14 randomized trials
comparing groups of patients given CBT-I to control
groups. A variety of controls were combined in that ana-
lysis, such as patients on a waiting list to receive CBT-I
and patients offered a sleep hygiene program which has
been shown to be of little or no benefit [17]. The meta-
analysis found that CBT-I had a medium to large effect
in reducing insomnia, and that the effects were main-
tained even after conclusion of the treatment period.
But this review does not tell us whether CBT-I is as
effective as sleep medications. The AHRQ Evidence-based Practice review [20] addressed that question, but
it was published in 2005 and lacks evidence published
since September 2004.
The primary objective of this review is to examine
the most up-to-date evidence comparing CBT-I to
medications in patients with primary and comorbid in-




We considered only published randomized controlled
trials (RCTs) with no exclusions based on date of publi-
cation or language. Inclusion criteria were defined in ad-
vance of data abstraction using the PICO framework
below [22].
Patients
Included studies examined patients aged 18 or older
diagnosed with chronic insomnia per DSM-IV criteria.
Studies of patients with medical or psychological comor-
bidities were included but analyzed separately, as were
studies of patients already using medications for insom-
nia. Studies with fewer than 10 patients in each group
were excluded.
Intervention
Study patients had to be treated with either individual or
group CBT-I to be included. Therapy had to be delivered
by a professional: studies of self-help programs were
excluded. Studies with telephone or internet sessions
were included if those sessions were supplementary to
in-person CBT-I. We did not set minimum or maximum
treatment periods for study inclusion. Studies that were
designed to compare individual elements of a CBT-I pro-
gram to each other were excluded.
Comparison
We examined all RCTs comparing CBT-I to FDA
approved prescription or non-prescription medications
used to treat insomnia both on- and off- label (e.g. ben-
zodiazepines, non-benzodiazepine receptor agonists,
antidepressants, and antihistamines).
Outcomes
Studies had to report at least one quantitative measure
of sleep to be included in this analysis. These measures
included sleep latency, wake after sleep onset, sleep effi-
ciency, total sleep time, and total wake time. Measures
from patients’ sleep diaries and measures from auto-
mated means (polysomnography and actigraphy) were
analyzed separately because of known unreliability in
patients’ perceptions of sleep. As secondary outcomes,
standardized measures of quality of life, sleep quality,
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iety, and fatigue were also abstracted when available, as
was data on adverse events.Literature searches and study inclusion/exclusion
We searched Medline (OVID interface, Additional file 1:
Table S1), the Cochrane Central Register (Additional file
1: Table S2), EMBASE (Additional file 1: Table S3), and
PsycINFO (Additional file 1: Table S4). Search strategies
combined indexing terms for CBT with indexing terms
for insomnia, then applied filters for randomized trials.
We did not limit the search to specific drugs. Detailed
syntax of each search is reported in the supplement. All
searches were completed in September 2011. We also
reviewed published systematic reviews [19,20,23] for eli-
gible RCTs which may have been missed by our searches:
none were found.
Disposition of the search hits and articles retrieved is
shown in Figure 1. Two research analysts (MDM, BL)
reviewed full text of each retrieved article to determine
whether it met the stated inclusion criteria. Disagree-
ments were resolved by a third reviewer (PG). Reasons
for exclusions of studies are summarized in Figure 1Records identified through
database searching








































Figure 1 PRISMA flow diagram for literature search and article inclusiand the complete list of excluded articles with reasons
for exclusion are in Additional file 1: Table S5.
Data abstraction and analysis
Study characteristics were abstracted into a database
with fields for study setting, patient selection criteria,
CBT-I interventions, and reviewers’ comments. This
database helped us decide how to organize studies and
evidence tables. Study results were then abstracted dir-
ectly into evidence tables. Data synthesis methods fol-
lowed the practice of the Cochrane Collaboration.
Assessment of RCT quality was done using a nine-point
scale (Additional file 1: Table S6) based on scales by
Jadad [24] and Chalmers [25]. Quality ratings for each
individual study are shown in Additional file 1: Table S7.
The overall quality of the evidence base for each com-
parison was rated using the GRADE approach [26-28].
Outcome measures
Key quantitative measures of sleep are sleep latency (the
amount of time it takes for a person to fall asleep after
retiring to bed), total sleep time (TST), time spent awake
after sleep onset, total wake time during the sleep period,













Too few patients: 5
Intervention did not meet 
inclusion criteria: 4
Did not compare
CBT-I to medication: 2
Sleep outcomes NR: 1
on.
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noted that TST is not only an outcome variable, but is
manipulated as part of CBT-I via the restriction of time
spent in bed. Specifically, sleep restriction therapy
requires that time in bed be reduced to a time interval
that equals the patient’s ‘sleep ability’ by measuring aver-
age TST during a two-week baseline period. The net re-
sult of this, after completion of CBT-I, is that many
patients do not recover their baseline TST but are never-
theless substantially improved with respect to other
aspects of sleep. This said, it is important to assess TST
as an outcome measure so that the effects of CBT-I are
fully characterized. There can also be substantial differ-
ences between automated measures of sleep time and
patients’ self-reports on sleep diaries.
Most studies reported these sleep outcomes for mul-
tiple time points. Where available, we tabulated results
for two of those points from each study: the time period
immediately following treatment, which for CBT-I was
typically 4 to 8 weeks from the start of therapy, and for
the longest follow-up period reported by study authors,
which was typically six to twelve months.
As secondary outcomes, we also analyzed results from
standardized patient questionnaires on sleep and insom-
nia symptoms, such as the Pittsburgh Sleep Quality
Index. Non-standard instruments, such as asking the pa-
tient to grade his or her sleep quality on a scale of 1 to
5, were not analyzed.
Daytime outcomes analyzed included standardized and
validated measures of patients’ general quality of life, and
measures of psychological outcomes including depres-
sion, anxiety, and fatigue.
Results
Our search found a total of five RCTs that met the inclu-
sion criteria and compared CBT-I to medications. The
five trials all involved patients with primary insomnia.
The trials compared CBT-I to zopiclone [29], zolpidem
[30], temazepam [31,32], and triazolam [33]. The design
and quality of these studies is reported in Table 1 and
their short and long term results are summarized in
Table 2 and Table 3 respectively. Only one trial com-
pared CBT-I to drug therapy in patients with comorbid
insomnia [34]: the drug used was nefazodone (now with-
drawn from the market), so the study was excluded from
further analysis. The evidence base was too small and
heterogeneous for meta-analysis.
Quantitative sleep outcomes
All trials asked patients to complete sleep diaries. All but
one also used polysomnography or actigraphs to object-
ively measure sleep outcomes. Reported sleep measures
included sleep latency, TST, and total time spent awake
during the night. Our results tables show the meanchanges in these variables from baseline to the end of
the active treatment period (Table 2) and the end of the
study follow-up period. Some studies reported inter-
mediate time points as well, which were consistent with
the initial and final results.
The evidence comparing benzodiazepines to CBT-I in
the short term is of very low grade (Table 4). One study
(meeting 3 of 9 quality points) found the benzodiazepine
temazepam to be statistically more effective than CBT-I
for improving sleep latency and sleep efficiency, while
another (meeting 6 of 9 quality points) found no dif-
ference (Table 2). Conversely, there is moderate grade
evidence suggesting CBT-I is superior to the non-
benzodiazepines zopiclone and zolpidem for improving
sleep measures in the short term.
Long-term studies (6 to 24 months after completion of
treatment) consistently favor CBT-I over both benzodiaze-
pines and non-benzodiazepines for improving sleep effi-
ciency, with moderate grade evidence for the former and
low grade evidence for the latter. CBT-I generally led to
improvements of 30 to 45 minutes in sleep latency and 30
to 60 minutes in total sleep time (Table 3). Sleep efficiency
improved 8 to 16 percent with CBT-I, but improved less
with drugs. The effects of CBT-I appear to be sustained
over time, while the effects of drug therapy decline.
Patients’ subjective evaluation of sleep
Only two of the studies reported results from standar-
dized sleep questionnaires given to patients at the end of
the follow-up period. Both reported that patients were
significantly more satisfied with CBT-I than with zopi-
clone, but they did so using different measures. In Mor-
in’s study [31] the Sleep Impairment Index declined 10
points after 24 months for patients treated with CBT-I,
but only 4 points for patients given tamezepam
(p = 0.01). Wu et al [32] surveyed patients using the
Pittsburgh Sleep Quality Index: after 8 months this
measure improved an average of 1.2 points in patients
treated with CBT-I, while it worsened 0.8 points in
patients given tamezepam (p< 0.01).
Quality of life and daytime outcomes
Evidence comparing CBT-I and medications for insom-
nia-related outcomes other than direct sleep measure-
ments is scarce. One trial [35] found no significant
difference in overall quality of life (SF-36) between
patients treated with CBT-I and patients treated with
zopiclone. This study also found no difference in daytime
fatigue between the two groups, as measured by patients’
reaction times. Quality of life outcomes were not
reported in the other trials.
The same trial also measured patients depression and
anxiety symptoms using several standard questionnaires.
Six months after treatment, scores were significantly
Table 1 Studies comparing CBT-I to pharmacological therapies: methods









Sievertsen 2006 [29] RCT 46 patients,







Study also included placebo group.
Zopiclone patients had option to
continue it after 6 week period.Norway 5 12 months
Daytime outcomes reported in [35]
CBT-I vs. zolpidem
Jacobs 2004 [30] RCT 63 patients,
age 25-64
Individual CBT-I,
5 sessions, 6 weeks;





Dose 10 mg→5 mg→5 mg q2d
over 6 week period.
USA 5 12 months
CBT-I vs. temazepam
Wu 2006 [32] RCT 77 patients Individual CBT-I





Dose 7.5 mg→30 mg→15 mg
over 8 week periodChina 3 8 months
Study also included placebo and
combined therapy groups
Morin 1999 [31] RCT 78 patients,







Dose 7.5 mg→30 mg as needed
over 8 week period
Study also included placebo and
combined therapy groups.
Canada 6 24 months
Adverse effects reported in [36]
Patient attitudes reported in [37]
CBT-I vs. triazolam
McCluskey 1991 [33] RCT 30 patients Group CBT-I 2 per week, 3 weeks Triazolam, 0.5 mg,
then tapered to 0
Sleep diaries Triazolam group also had weekly



















Table 2 Studies comparing CBT-I to pharmacological therapies: post-treatment results








Other Adverse effects Notes
CBT-I vs. zopiclone SWS
Sievertsen 2006 [29]
6 weeks
CBT-I: 18 Not reported –26.2 min –56.4 min +7.5% +17.2 min None
Zopiclone: 16 –65.6 min –3.9 min –0.8% –15.1 min 1 withdrawal
p = NS p < 0.001 p = NS p = 0.002Polysomnography
Sleep diary CBT-I: 18 Not reported +16.9 min –48.3 min +11.8%
Zopiclone: 16 +34.6 min –25.8 min +8.1%
p = NS p = NS p = NS
CBT-I vs. zolpidem
Jacobs 2004 [30] CBT-I: 13 –15.5 min –2.6 min Not reported +5.5% No withdrawals
due to side effects




8 weeks Zolpidem: 12 –6.1 min –51.6 min +2.1%
Sleep monitor p = NS p = NR p = NS
Sleep diary CBT-I: 13 –33.8 min +48.6 min Not reported +17.3%
Zolpidem: 12 –12.8 min +69.2 min +2.1%
p < 0.05 p = NR p = 0.007
CBT-I vs. temazepam WASO
Wu 2006 [32] CBT-I: 19 –35.9 min +21.6 min Not reported +9.2% Not reported p values based on
post-intervention
differences
8 weeks Temazepam: 17 –44.9 min +66.5 min +14.3%
Polysomnography p < 0.01 p < 0.004 p < 0.05
Sleep diary CBT-I: 19 –37.0 min +38.7 min Not reported +13.4%
Temazepam: 17 –53.2 min +73.5 min +15.1%
p < 0.001 p < 0.01 p < 0.01
Morin 1999 [31] CBT-I: 18 Not reported +6.8 min Not reported +8.5% –32.5 min Not reported
8 weeks Temazepam: 17 +35.3 min +7.5% –23.3 min
Polysomnography p = NS p = NS p = NS
Sleep diary CBT-I: 18 Not reported +30.5 min Not reported +16.5% –27.3 min
Temazepam: 17 +43.7 min +10.3% –25.6 min
p = NS p = NS p = NS
CBT-I vs. triazolam
McCluskey 1991 [33] CBT-I: 15 –44 min +40 min Not reported Not reported Not reported
3 weeks Triazolam :15 –45 min +57 min
Sleep diary p = NS p = NS



















Table 3 Studies comparing CBT-I to pharmacological therapies: follow-up results
Study Group Sleep latency Total sleep time Total wake time Efficiency Other Notes
CBT-I vs. zopiclone SWS
Sievertsen 2006 [29] CBT-I: 18 Not reported –5.0 min –60.7 min +8.7% +21.1 min
Zopiclone :16 –56.2 min –9.9 min –0.4% –17.6 min
6 months p = NS p = 0.01 p = 0.008 p = 0.001
Polysomnography
Sleep diary CBT-I: 18 Not reported +42.4 min –73.3 min +14.2%
Zopiclone :16 +40.5 min –42.2 min +10.7%
p = NS p = 0.03 p = NS
CBT-I vs. zolpidem
Jacobs 2004 [30] CBT-I: 8 No long-term follow-up for
zolpidem group12 months Zolpidem: none
Sleep diary
CBT-I vs. temazepam WASO
Wu 2006 [31] CBT-I: 19 –32.8 min +30.3 min Not reported +10.2% p values based on post-
intervention differences8 months Temazepam: 17 –17.2 min –13.0 min –1.9%
Polysomnography p < 0.004 p < 0.05 p < 0.01
Sleep diary CBT-I: 19 –41.8 min 45.5 min Not reported +16.8%
Temazepam: 17 –20.5 min –6.0 min +3.9%
p < 0.003 p < 0.01 p < 0.05
Morin 1999 [31] CBT-I: 13 Not reported +65.2 min Not reported +16.4% –16.5 min All measurements in
temazepam group significantly
worsened from end of treatment
to end of follow-up.
24 months
Sleep diary Temazepam: 12 +11.5 min +2.9% –4.6 min
p = NR p = NR p = NR
CBT-I vs. triazolam
McCluskey 1991 [33] CBT-I: 15 –45 min +51 min Not reported Not reported
8 weeks Triazolam :15 –21 min +14 min
Sleep diary p < 0.01 p = NR













































Short term Improved less
with CBT-I
3 RCT High –2 –1 0 0 0 0 0 0 Very low
Long term Improved more
with CBT-I
3 RCT High –1 0 0 0 0 0 0 0 Moderate
CBT-I vs.
non-benzodiazepines
Short term Improved more
with CBT-I
2 RCT High –1 0 0 0 0 0 0 0 Moderate
Long term Improved more
with CBT-I
1 RCT High –1 0 0 –1 0 0 0 0 Low
Evidence assessed using methods of the GRADE Working Group [26-28].
Evidence strength ratings:
High: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low: Any estimate of effect is very uncertain.
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Index for CBT-I patients compared to zopiclone patients
(state: –5.11 vs. +1.61, p< 0.05; trait: –4.47 vs. +1.97,
p< 0.01). Trends towards improved results with CBT-I
were observed in the Penn State Worry Questionnaire
and the Worry Domains Questionnaire, but the differ-
ences between groups were not statistically significant.
No difference between groups was observed in the In-
ventory of Interpersonal Problems.
Adverse effects of treatment
Reporting of adverse events in all of these trials is lim-
ited, so we cannot draw any conclusions regarding the
relative safety of CBT-I compared to benzodiazepines
and non-benzodiazepines.
We found no trials comparing CBT-I to antihistamines
or antidepressants.
Discussion
Overall, we found that CBT-I is at least as effective
for treating insomnia when compared with sleep medi-
cations, and its effects may be more durable than medi-
cations. The strength of these claims needs to be
tempered with a critical evaluation of the available evi-
dence. There have only been a handful of studies that
have included both cognitive behavioral and pharmaco-
therapy treatment arms for inclusion in this systematic
review. A significant limitation of the studies is that they
all focused on patients with primary insomnia who,
while more straightforward for inclusion in clinical stud-
ies, may not be representative of the majority of patients
who have comorbid medical or psychiatric disorders.
RCTs of CBT-I only, with no medication comparator
condition, generally find that treatment is as efficacious
in those with comorbid disorders compared to those
with primary insomnia (for example see [38]). While
this suggests that the results of this review may also
hold for comorbid insomnia, studies including both
CBT-I and medication arms are needed in this patient
population. The studies also were diverse in terms of
sleep-related outcome measures (subjective versus ob-
jective) and demographic composition. In terms of out-
come measures, insomnia RCTs generally find larger
effects of treatment on subjective measures such as
questionnaires than on objective measures of actigraphy
and polysomnography. However, this does not limit the
meaning of the findings since the diagnosis of insomnia
relies on patient report and not on a diagnostic labora-
tory test. In terms of demographic composition, three of
the five studies we included were in older adults. Future
studies will need to be conducted in both older and
younger adult samples, but it is noteworthy that the
findings were generally consistent across studies despite
the diversity of subject ages.The results of this analysis indicate that more research
is warranted in this area to better understand the relative
efficacy of CBT-I and hypnotics in order to make deci-
sions about best practices.
Even with these limitations, these results have a number
of important treatment implications for the primary care
setting. First, providers should consider CBT-I as a treat-
ment option for their patients with insomnia. Second, CBT-
I may have advantages when compared to medications,
most notably more durable treatment gains that reduce or
eliminate the need for long-term pharmacologic treatment.
In addition, those significant clinical gains can be made in a
relatively short number of treatment sessions (most studies
were 6–8 weekly or bi-weekly sessions). Future research
comparing the efficacy of CBT-I and hypnotics may find
that treatment efficacy is moderated by patient characteris-
tics such as age or comorbid diagnoses. These data can lead
to the development of treatment algorithms that would
allow primary care providers to make more informed treat-
ment decisions. Of note, three of the studies [29,31,32]
included a treatment arm that was a combination of CBT-I
and medication. Outcomes were generally comparable to
those receiving CBT-I alone, but future studies should
examine additional strategies for combination treatment
that capitalize on the relative advantages of medication
(rapid onset on therapeutic response) and CBT-I (long-term
durability of treatment gains).
Despite the evidence supporting the effectiveness of
CBT-I, many providers may not be aware of its existence
or know how to refer patients for treatment [39]. Referral
can be accomplished in several ways. First, there is a
growing registry of providers who have sought specialized
certification in the delivery of CBT-I and other behavioral
sleep medicine interventions to whom patients can be re-
ferred (http://www.absm.org/BSMSpecialists.aspx). These
providers are primarily clinical psychologists and are
located in a variety of settings including sleep disorders
centers and private practice [14,40]. Second, primary care
practices can partner with local psychologists or others to
provide CBT-I. Lastly, a few studies have yielded promis-
ing results by implementing CBT-I in the primary care
setting by nurses provided the necessary training and
supervision [41,42]. By utilizing these various approaches,
primary care providers can make CBT-I accessible. Yet,
even with these options, getting a patient access to CBT-I
may present challenges not encountered when providing
a patient with a simple prescription for a sleep medica-
tion. First, there can be greater difficulty in getting insur-
ance coverage for CBT-I than for medications. Second,
therapists to provide CBT-I may not be available in some
parts of the country or the world. However, the evidence
reviewed in this manuscript suggests that the additional
effort in obtaining access to a therapist if available may be
worth the more long-term improvements patients may
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medications.
The GRADE approach used to grade the evidence base
for the comparisons examined in this study can help iden-
tify areas where the evidence is least robust and where
additional studies can most impact our conclusions about
CBT-I. GRADE can also help identify causes for the weak-
ness of the evidence base. Data on long-term outcomes of
CBT-I compared to non-benzodiazepines is still sparse,
and inconsistencies in the data comparing CBT-I to ben-
zodiazepines in the short term need to be resolved. Data
on CBT-I for patients in critical subgroups of interest such
as those with comorbid insomnia is sparse as well, and
there have been no trials comparing CBT-I to approved
drugs in these patients. This is an important limitation of
the findings in our review as many patients presenting
with insomnia to primary care practices will have second-
ary or co-morbid insomnia, and thus the findings here
may not be as generalizable to those settings. In addition,
comparisons of CBT-I to drugs commonly used off-label
for the treatment of insomnia, including antidepressants
and antihistamines, are not available. Lastly, all studies in
this field suffer an unavoidable risk of bias because
double-blinding is not possible.
Conclusion
CBT-I is an effective treatment for insomnia that can pro-
duce durable results in a relatively brief number of visits.
Low- to moderate quality evidence suggests it has greater
effectiveness than medications for treatment of insomnia
six months or more after therapy is completed. Additional
research is needed to validate its effectiveness in long-term
studies beyond 1–2 years and in patients with comorbid in-
somnia. Additional research is also needed to establish a
benefit for CBT-I with respect to important psychological
outcomes including quality of life.
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